Myofascial Pain Syndrome
Conditions
Keywords
ESWT, myofascial pain syndrome
Brief summary
To investigate the efficacy and safety according to the frequency of focused ESWT in patients with myofascial pain syndrome.
Detailed description
Myofascial pain syndrome is one of the common causes of musculoskeletal pain seen in clinical practice and is characterized by the presence of trigger points associated with sensitive areas such as taut bands of skeletal muscle. It may also be accompanied by referred pain, which is pain in other parts of the body. Although the pathophysiology and etiology of myofascial pain syndrome and trigger points are still unknown, there are reports that myofascial pain is a complex form of neuromuscular dysfunction caused by motor and sensory abnormalities involving both the peripheral nervous system and the central nervous system. Recently, it has been considered as a method of treatment for myofascial pain syndrome. In addition, although pain reduction and functional improvement of focused ESWT in patients with myofascial pain syndrome have been reported, related studies are lacking on the effect of focused ESWT according to the frequency difference. The purpose of the study is to examine the efficacy and safety of focused type ESWT frequency in patients with myofascial pain syndrome.
Interventions
DEVICEExtracorporeal shockwave therapy
Treatment Location: Painful Area Treatment intensity: 2000 pulses, low energy (0.08\ 0.28 mJ/m2) the degree to which the subject can tolerate
Sponsors
CHA University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Those diagnosed with myofascial pain syndrome according to Simon's criteria 2. Pain is 4 points or more on the Numerical Rating Scale (NRS)
Exclusion criteria
1. Pain is due to trauma, fibromyalgia and neurological disorders including neuromyopathy, myelopathy, and stroke 2. If you have received injection treatment for trigger points within the last 2 months or have had surgery on the painful area within 1 year 3. If there is a high risk of bleeding due to severe coagulopathy, etc. or if you have recently had severe bleeding (except taking antiplatelet) 4. If you have a tumor, infection, kidney failure, severe liver disease, epilepsy, skin disease, or mental retardation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline NRS (numerical rating scale) at each time frame | baseline, immediately after primary treatment, 1 day after primary treatment, 3 day after primary treatment, immediately after secondary treatment, 1 day after secondary treatment, 3 day after secondary treatment | Pain intensity (0-10, ordinal scale) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of treatment-related adverse events as assessed by CTCAE v4.0 at each time frame | immediately after primary treatment, 1 day after primary treatment, 3 day after primary treatment, immediately after secondary treatment, 1 day after secondary treatment, 3 day after secondary treatment | Common Terminology Criteria for Adverse Events |
Countries
South Korea
Contacts
Primary ContactKyunghoon Min, MD, PhD
Outcome results
None listed